Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 71205-812

This appears to be a list of drug interactions and their effects on the pharmacokinetics of a drug called venlafaxine. The interactions include other drugs such as ethanol, diazepam, and ketoconazole, and also mention the enzyme CYP2D6. The text provides recommendations on how to adjust the dosage or avoid concomitant use of the interacting drugs to prevent adverse effects.*

This text appears to provide guidance on dosage adjustments for venlafaxine, a medication used in the treatment of depression and anxiety, based on a patient's specific demographic and health characteristics. The recommendations are categorized by hepatic impairment, renal impairment, CYP2D6 polymorphism, age, and gender. For each population, adjustments to the maximum concentration (Cmax) and the area under the curve (AUC) of the medication are suggested, with some requiring individualized dosing. The text also includes a chart displaying the relative change in fold for various conditions.*

This is a description of Venlafaxine HCI ER capsules, with each one containing 37.5mg of venlafaxine hydrochloride USP. The capsules are off-white, round to oval-shaped pellets filled in size '3' hard gelatin capsules with a grey opaque cap imprinted with 'V' in black color, and a white opaque body imprinted with '9" in black color. The medication guide should be provided to each patient. The capsules have been manufactured by Annora Pharma Pvt. Ltd. and packaged by Proficient Rx LP. The medication must be stored at 20°-25°C (68°-77°F) and kept out of the reach of children. The product ID is QV081230, and there are 30 capsules per package. Finally, the lot number is 00000, and the expiration date for the medication is 00/00/00.*